Emergent BioSolutions vs OPKO Health
EBS and OPK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EBS and OPK compare
OPKO Health is the larger company, worth 4.2 times as much as Emergent BioSolutions ($1.3B against $297M).
OPKO Health grew revenue faster over the last twelve months (−8.3% versus −17.7% for Emergent BioSolutions).
OPKO Health keeps more of each dollar of sales as profit, with a net margin of −29.5% compared with −40.2% at Emergent BioSolutions.
OPKO Health scores higher on the StockData Score (8 against 6 for Emergent BioSolutions), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EBS | OPK |
|---|---|---|
| Size and price | ||
| Market cap | $297M | $1.3B |
| Share price | $5.79 | $1.68 |
| Change, 1 year | −46.4% | 27.3% |
| Change, 5 years | −85.6% | −61.4% |
| Beta (5Y) | 1.84 | 0.92 |
| Employees | 900 | 2,275 |
| StockData Score | ||
| Total score | 6 | 8 (better) |
| Valuation score | 3 (better) | 2 |
| Growth score | 0 | 1 (better) |
| Performance score | 1 | 2 (better) |
| Health score | 2 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.5× (better) | 2.5× |
| P/B | 0.9× (better) | 1.1× |
| P/FCF | 1.6× | – |
| FCF yield | 63.5% (better) | −10.8% |
| Fair value | $20.75 | $2.10 |
| Margin of safety | 72.1% (better) | 20.0% |
| Growth | ||
| Revenue growth (TTM) | −17.7% | −8.3% (better) |
| Revenue growth, 5Y average | −14.0% (better) | −15.8% |
| Net income growth (TTM) | −443% | – |
| EPS growth (TTM) | −486% | – |
| EPS growth, 5Y average | −30.4% | – |
| Profitability | ||
| Gross margin | 48.4% | 56.6% (better) |
| Operating margin | −27.7% | −17.5% (better) |
| Net margin | −40.2% | −29.5% (better) |
| FCF margin | 29.0% (better) | −27.0% |
| Return on equity | −58.2% | −12.2% (better) |
| Return on invested capital | −17.3% | −8.5% (better) |
| Financial health | ||
| Debt / equity | 1.62 | 0.00 (better) |
| Interest coverage | −4.0× | – |
| Current ratio | 4.58 | 4.97 (better) |
| Altman Z-score | 0.33 (better) | −0.28 |
| Piotroski F-score | 7 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | 9.2% (better) | 3.3% |
| Shareholder yield | 9.2% (better) | 3.3% |
| Ownership | ||
| Held by institutions | 87.1% | 27.2% |
| Held by insiders | 6.0% | 43.6% |
| Insider net buying, 12 months | −$986K | −$13.2K (better) |
| Short interest, % of float | 20.9% | 7.8% |
Go deeper
- EBS stock overview
- EBS income statement
- EBS valuation and score
- OPK stock overview
- OPK income statement
- OPK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.